文献速递前列腺增生与排尿功能障碍

奥那波妥钠毒素A治疗膀胱过度活动症伴尿失禁患者:一项3期随机安慰剂对照试验结果

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
PubMed 文献 · J Urol · 2016-12-22

这是一项纳入557例患者的3期随机安慰剂对照试验,患者为抗胆碱能药物控制不佳的膀胱过度活动症伴尿失禁者。第12周时,奥那波妥钠毒素A 100 U组每日尿失禁发作次数较基线的降幅大于安慰剂组,治疗获益量表阳性反应比例更高,不良事件以无并发症尿路感染最常见。

要点

  • 奥那波妥钠毒素A 100 U组每日尿失禁发作次数较基线减少2.65次,安慰剂组减少0.87次(p<0.001)。
  • 奥那波妥钠毒素A 100 U组22.9%的患者完全控尿,安慰剂组为6.5%。
  • 奥那波妥钠毒素A 100 U组治疗获益量表阳性反应比例为60.8%,安慰剂组为29.2%(p<0.001)。

核心结论

  • 对于抗胆碱能药物治疗不充分的膀胱过度活动症伴尿失禁患者,奥那波妥钠毒素A 100 U在所有膀胱过度活动症症状和健康相关生活质量方面均显示出显著且有临床意义的改善,且耐受性良好。

研究设计与样本

  • 这是一项3期随机安慰剂对照试验,共纳入557例患者;患者需在3天内至少有3次急迫性尿失禁发作且每日排尿次数至少8次。
  • 患者按1:1随机接受膀胱逼尿肌内注射奥那波妥钠毒素A 100 U或安慰剂。

主要发现

  • 奥那波妥钠毒素A组每日尿失禁发作次数较基线减少2.65次,安慰剂组减少0.87次(p<0.001)。
  • 奥那波妥钠毒素A组22.9%的患者完全控尿,安慰剂组为6.5%。
  • 奥那波妥钠毒素A组60.8%的患者报告治疗获益量表阳性反应,安慰剂组为29.2%(p<0.001)。
  • 所有其他膀胱过度活动症症状较安慰剂组均有改善(p≤0.05);患者健康相关生活质量在多项指标上改善(p<0.001)。
  • 无并发症尿路感染是最常见的不良事件;观察到5.4%的尿潴留发生率。

关键数值与推荐

  • 共同主要终点为每日尿失禁发作次数较基线的变化,以及治疗后第12周治疗获益量表阳性反应的患者比例。
  • 次要终点包括其他膀胱过度活动症症状和健康相关生活质量,并评估不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics. MATERIALS AND METHODS: Eligible patients with overactive bladder, 3 or more urgency urinary incontinence episodes in 3 days and 8 or more micturitions per day were randomized 1:1 to receive intradetrusor injection of onabotulinumtoxinA 100 U or placebo. Co-primary end points were the change from baseline in the number of urinary incontinence episodes per day and the proportion of patients with a positive response on the treatment benefit scale at posttreatment week 12. Secondary end points included other overactive bladder symptoms and health related quality of life. Adverse events were assessed. RESULTS: OnabotulinumtoxinA significantly decreased the daily frequency of urinary incontinence episodes vs placebo (-2.65 vs -0.87, p <0.001) and 22.9% vs 6.5% of patients became completely continent. A larger proportion of onabotulinumtoxinA than placebo treated patients reported a positive response on the treatment benefit scale (60.8% vs 29.2%, p <0.001). All other overactive bladder symptoms improved vs placebo (p ≤0.05). OnabotulinumtoxinA improved patient health related quality of life across multiple measures (p <0.001). Uncomplicated urinary tract infection was the most common adverse event. A 5.4% rate of urinary retention was observed. CONCLUSIONS: OnabotulinumtoxinA 100 U showed significant, clinically relevant improvement in all overactive bladder symptoms and health related quality of life in patients inadequately treated with anticholinergics and was well tolerated.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2016. PMID: 28012773. doi:10.1016/j.juro.2016.10.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。